Abstract:
Stroke continues to be the world’s primary cause of morbidity and mortality, frequently with
incapacitating consequences like movement dysfunction, cognitive decline, and neurological
impairments. It is essential to manage stroke effectively to lessen its negative effects and
enhance patient outcomes. The potential neuroprotective benefits of acetylcholinesterase
inhibitors may assist maintain the integrity of brain tissue and lessen the damage that neurons
may sustain after a stroke, making them a promising option in this situation. This
comprehensive thesis explores the neuroprotective benefits of an acetylcholinesterase inhibitor,
Rivastigmine, in relation to stroke outcomes in a variety of ways. Using an advanced
integrative methodology, this study includes behavioral evaluations, in silico analysis,
histopathological results, and molecular studies to give a comprehensive picture of the possible
mechanisms behind therapeutic effects of Rivastigmine. Within the field of computer
modelling, the docking interactions between SOD2 and TLR4, the target proteins of
Rivastigmine, provide detailed structural information that directs further experimental
validations. Following Rivastigmine treatment, the behavioral tests conducted exhibited
improvements in cognitive, motor, and social domains. These results were further corroborated
by histopathological analysis, which shows neuroprotective effects in Rivastigmine treated
group as opposed to surgery (MCAO) group. Post Rivastigmine treatment, real-time PCR data
showed a rise in SOD2 and a decrease in TLR4 levels in surgery (MCAO) rats, exhibiting
antioxidant and anti-inflammatory effects of Rivastigmine. These findings provide interesting
directions for future neuroprotective approaches and shed light on the possible therapeutic
implications of Rivastigmine in reducing neurodegeneration that occurs in stroke.
